Edwards Lifesciences makes a simple change for a first-of-its-kind tricuspid valve

Edwards Lifesciences received FDA approval in May 2026 for Triformis Resilia, the first surgical valve designed specifically for the tricuspid position. The device incorporates a design modification that addresses an unmet clinical need in tricuspid valve replacement, marking a new product entry in the structural heart device market.